#AUA14 - Poster: Overactive bladder patients ≥ 65 years of age have a similar efficacy and safety profile with onabotulinumtoxinA as patients less than 65 years of age

ORLANDO, FL USA (UroToday.com) - Presented by Courtenay Moore,¹ Albert Kaufmann,² Manher Joshi,³ Christopher Nardo,³ Yan Zheng,⁴ and Sender Herschorn⁵ at the American Urological Association (AUA) Annual Meeting - May 16 - 21, 2014 - Orlando, Florida USA

¹Cleveland Clinic, Cleveland, OH, USA; ²Kliniken Maria Hilf GmbH, Mönchengladbach, Germany; ³Allergan, Inc., Irvine, CA, USA; ⁴Allergan, Inc., Bridgewater, NJ, USA; ⁵University of Toronto, Toronto, ON, Canada